

## **Methodological Note**

Alexion Pharma UK Ltd has used the following methodologies in the preparation of the ABPI disclosure

of the transfer of value to healthcare professionals and healthcare organisations:

1. All qualifying transfers of value made by an Alexion affiliated company to a UK Healthcare professional or Organization will be declared
2. Direct transfers of value by Alexion to a healthcare professional or healthcare organisation will be declared at the date of payment
3. Transfers of value made via a 3<sup>rd</sup> party organization will be declared at the date of the event
4. Where a transfer of value is made in a currency other than GBP Alexion will convert at HMRC 2017 average exchange rates.
5. Where a transfer of value is made to a healthcare professional indirectly via a healthcare organization, Alexion will disclose the value the transfer in the name of the healthcare professional as recommended by article 24.8 of the ABPI code.
6. Any payment related to the transfer of value for Research and Development to individual healthcare professionals, as per clause 23.2 of the ABPI code, is declared as an aggregate and not individually.
7. Subsequent to any written consent of disclosure if a healthcare professional states they no longer wish Alexion to disclose any further transfers of value then this will retrospectively apply for the reporting period. All transfers of value for the reporting period will go into the aggregate
8. Where Alexion Pharmaceuticals did not receive a written consent sent to HCPs, all transfers of value for the reporting period will go into the aggregate.